Answers are grounded in this paper and cite their sources.
BACKGROUNDType 1 gastric neuroendocrine tumors (g-NETs) originate from autoimmune gastritisinduced enterochromaffin-like (ECL) cell hyperplasia.Although ECL cell hyperplasia is an established precursor lesion, its dose-response relationship with tumor progression remains poorly defined. AIMTo characterize the dose-response relationship of ECL hyperplasia grade with progression and develop a prognostic nomogram for type 1 g-NETs. METHODSWe conducted a single-center retrospective cohort study involving 107 patients with type 1 g-NETs.ECL hyperplasia was graded 0-4 according to the Solcia classification system.Progression was defined as increased NET number or maximum diameter.Progressionfree survival was analyzed by multivariable Cox regression, with time-varying Cox used for traditional Chinese medicine (TCM); dose-response by Cochran-Armitage test; longitudinal predictors by generalized estimating equations (GEE).A nomogram was constructed.Missing data were addressed by complete-case analysis, with multiple imputation for sensitivity analysis. RESULTSOver a median follow-up of 49.9 months, 47 of 107 patients (43.9%) showed disease progression.ECL hyperplasia grade showed a significant dose-response trend with progression (Cochran-Armitage χ 2 = 14.56,P < 0.001); this association remained significant in the GEE model excluding outcome-constituting covariates (odds ratio = 1.47, 95% confidence interval (CI): 1.19-1.81,P < 0.001), but was attenuated to 4 / 54 nonsignificance after adjustment for tumor burden.Baseline multivariable Cox regression identified autoimmune thyroid disease (AITD) as a protective factor [hazard ratio (HR) = 0.24, 95%CI: 0.10-0.53,P < 0.001].TCM use was associated with a favorable progression profile in subsequent time-varying Cox analyses (HR = 0.43, 95%CI: 0.22-0.84,P = 0.014).Furthermore, a four-variable nomogram (C-index = 0.683) successfully stratified patients into three risk groups (log-rank P < 0.001).CONCLUSION ECL hyperplasia grade serves as a surveillance marker of tumor burden rather than an independent prognostic factor; AITD is protective; the nomogram requires external validation; and TCM effects require further confirmation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: